160 related articles for article (PubMed ID: 23337928)
1. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia.
Schwaederlé M; Ghia E; Rassenti LZ; Obara M; Dell'Aquila ML; Fecteau JF; Kipps TJ
Leukemia; 2013 Apr; 27(5):1214-7. PubMed ID: 23337928
[No Abstract] [Full Text] [Related]
2. SF3B1 mutations in chronic lymphocytic leukemia.
Wan Y; Wu CJ
Blood; 2013 Jun; 121(23):4627-34. PubMed ID: 23568491
[TBL] [Abstract][Full Text] [Related]
3. Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells.
Wu X; Tschumper RC; Jelinek DF
Leukemia; 2013 Nov; 27(11):2264-7. PubMed ID: 23685408
[No Abstract] [Full Text] [Related]
4. Chronic lymphocytic leukemia with SF3B1 mutation.
Quesada V; Ramsay AJ; Lopez-Otin C
N Engl J Med; 2012 Jun; 366(26):2530. PubMed ID: 22738114
[No Abstract] [Full Text] [Related]
5. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.
Rossi D; Rasi S; Spina V; Fangazio M; Monti S; Greco M; Ciardullo C; Famà R; Cresta S; Bruscaggin A; Laurenti L; Martini M; Musto P; Forconi F; Marasca R; Larocca LM; Foà R; Gaidano G
Br J Haematol; 2012 Aug; 158(3):426-9. PubMed ID: 22571487
[No Abstract] [Full Text] [Related]
6. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
7. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
8. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.
Quesada V; Conde L; Villamor N; Ordóñez GR; Jares P; Bassaganyas L; Ramsay AJ; Beà S; Pinyol M; Martínez-Trillos A; López-Guerra M; Colomer D; Navarro A; Baumann T; Aymerich M; Rozman M; Delgado J; Giné E; Hernández JM; González-Díaz M; Puente DA; Velasco G; Freije JM; Tubío JM; Royo R; Gelpí JL; Orozco M; Pisano DG; Zamora J; Vázquez M; Valencia A; Himmelbauer H; Bayés M; Heath S; Gut M; Gut I; Estivill X; López-Guillermo A; Puente XS; Campo E; López-Otín C
Nat Genet; 2011 Dec; 44(1):47-52. PubMed ID: 22158541
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Rossi D; Bruscaggin A; Spina V; Rasi S; Khiabanian H; Messina M; Fangazio M; Vaisitti T; Monti S; Chiaretti S; Guarini A; Del Giudice I; Cerri M; Cresta S; Deambrogi C; Gargiulo E; Gattei V; Forconi F; Bertoni F; Deaglio S; Rabadan R; Pasqualucci L; Foà R; Dalla-Favera R; Gaidano G
Blood; 2011 Dec; 118(26):6904-8. PubMed ID: 22039264
[TBL] [Abstract][Full Text] [Related]
10. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.
Gentien D; Kosmider O; Nguyen-Khac F; Albaud B; Rapinat A; Dumont AG; Damm F; Popova T; Marais R; Fontenay M; Roman-Roman S; Bernard OA; Stern MH
Leukemia; 2014 Jun; 28(6):1355-7. PubMed ID: 24434863
[No Abstract] [Full Text] [Related]
11. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia.
Mansouri L; Cahill N; Gunnarsson R; Smedby KE; Tjönnfjord E; Hjalgrim H; Juliusson G; Geisler C; Rosenquist R
Leukemia; 2013 Feb; 27(2):512-4. PubMed ID: 23138133
[No Abstract] [Full Text] [Related]
12. The impact of SF3B1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract][Full Text] [Related]
13. Predicting treatment outcomes in CLL.
Wiestner A
Blood; 2014 May; 123(21):3212-4. PubMed ID: 24855188
[TBL] [Abstract][Full Text] [Related]
14. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.
Cortese D; Sutton LA; Cahill N; Smedby KE; Geisler C; Gunnarsson R; Juliusson G; Mansouri L; Rosenquist R
Leukemia; 2014 Mar; 28(3):710-3. PubMed ID: 24217197
[No Abstract] [Full Text] [Related]
15. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Dreger P; Schnaiter A; Zenz T; Böttcher S; Rossi M; Paschka P; Bühler A; Dietrich S; Busch R; Ritgen M; Bunjes D; Zeis M; Stadler M; Uharek L; Scheid C; Hegenbart U; Hallek M; Kneba M; Schmitz N; Döhner H; Stilgenbauer S
Blood; 2013 Apr; 121(16):3284-8. PubMed ID: 23435461
[TBL] [Abstract][Full Text] [Related]
16. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
17. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
[TBL] [Abstract][Full Text] [Related]
18. Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.
Greco M; Capello D; Bruscaggin A; Spina V; Rasi S; Monti S; Ciardullo C; Cresta S; Fangazio M; Gaidano G; Foà R; Rossi D
Hematol Oncol; 2013 Mar; 31(1):54-5. PubMed ID: 22461140
[No Abstract] [Full Text] [Related]
19. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
